IQVIA (NYSE:IQV – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 11.100-11.200 for the period, compared to the consensus earnings per share estimate of 11.210. The company issued revenue guidance of $15.4 billion-$15.4 billion, compared to the consensus revenue estimate of $15.5 billion. IQVIA also updated its FY24 guidance to $11.10-11.20 EPS.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on IQV shares. Robert W. Baird lifted their target price on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Truist Financial decreased their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $267.27.
Check Out Our Latest Stock Report on IQVIA
IQVIA Trading Down 2.7 %
Insider Activity
In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
- Five stocks we like better than IQVIA
- What is the S&P/TSX Index?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- The Role Economic Reports Play in a Successful Investment Strategy
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- The How And Why of Investing in Oil Stocks
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.